1 Min Read
April 13 (Reuters) - Aimmune Therapeutics Inc
* Aimmune Therapeutics appoints Eric Bjerkholt as Chief Financial Officer
* Aimmune Therapeutics Inc - Bjerkholt joins Aimmune from Sunesis Pharmaceuticals, Inc.
* Aimmune - Co plans to report pivotal phase 3 data around end of 2017, file a BLA and MAA in 2018, and make first commercial launches in 2019 for AR101 Source text for Eikon: Further company coverage: